Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
7.30
Ask:
7.50
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Collaboration with Future Processing

28 Jul 2016 13:31

RNS Number : 5501F
Feedback PLC
28 July 2016
 

28 July 2016

 

Feedback plc

("Feedback" or the "Company")

Collaboration with Future Processing

 

Feedback plc (AIM: FDBK), the medical imaging software company is pleased to announce a large-scale collaboration with Future Processing Sp. z o.o. ("Future Processing"), a software development service provider based in Gliwice, Poland to develop medical imaging software. The collaboration will entail a substantially increased development team working on new products and the sharing of intellectual property and future revenues. This collaboration has resulted from Feedback's assistance with a successful EU grant application made by Future Processing.

In September 2015, Mike Hayball, CEO of Cambridge Computed Imaging Limited, a wholly owned subsidiary of Feedback, ("CCI") and Executive Director of Feedback, and Dr Stephen Brown, COO of CCI, began assisting Future Processing with a grant application to develop an innovative quantitative imaging product. The grant application was subsequently successful and has led to a significant expansion of the Future Processing healthcare team. CCI has had a working relationship with Future Processing since 2005.

The directors of Feedback believe that by CCI working jointly with the Future Processing healthcare team, CCI's existing product portfolio can be improved and new products developed more rapidly including further applications for TexRAD. Although at this stage only a non-binding letter of intent has been agreed, the intention is for the Company to agree formal licences for new software products to be brought to market in 2017/18 under a shared revenue arrangement. In the current financial year, the Company will make substantial savings in software development costs and thereafter expects to benefit from its share of the revenue from sales of the new products.

"This is an exciting opportunity to expand the relationship with Future Processing to build a talented, dynamic team of medical imaging specialists." said Mike Hayball, CEO of CCI.

"We are excited about this joint project. Together with CCI we will develop medical imaging software and bring innovative solutions to the healthcare sector." said Jarosław Czaja, CEO of Future Processing.

For further information, contact:

Feedback plcAlastair Riddell / Mike Hayball / Trevor Brown

Tel: 01954 718072

Allenby Capital Limited (Nominated Adviser and Joint Broker)David Worlidge / James Thomas

Tel: 020 3328 5656

Peterhouse Corporate Finance Ltd (Joint Broker)Lucy Williams / Duncan Vasey

Tel: 020 7469 0936

 

 

Founded in 2001, CCI specialises in providing software for display, capture and analysis of medical images. Since its foundation, when it focused on supporting the needs of Papworth Hospital, the UK's largest specialist cardiothoracic hospital, CCI has worked with facilities where its software is used to support diagnosis, plan treatment, measure response and share knowledge within multi-disciplinary teams. From 2011, CCI has worked with TexRAD and has been responsible for developing the innovative quantitative textural analysis platform.

Future Processing is an experienced Polish offshore software development service provider, working mostly with European companies located in the UK and Scandinavia. Since January 2016, it has been a strategic partner of Microsoft. Future Processing currently employs over 700 people and simultaneously runs more than 50 projects. Based in the heart of Upper Silesia, it is at the hub of European software talent, technical expertise and innovation. The new healthcare team consists of experienced scientists and engineers with extensive experience of software development, medical image processing, and machine learning.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPGUCPMUPQGPR
Date   Source Headline
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement
20th Apr 20157:00 amRNSAdoption of TexRAD research software
13th Apr 20157:00 amRNSCollaboration with the Oxford Stone Group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.